Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab

Alessandro Rambaldi,Giuseppe Gritti,Maria Caterina Micò,Marco Frigeni,Gianmaria Borleri, Anna Salvi,Francesco Landi,Chiara Pavoni,Aurelio Sonzogni,Andrea Gianatti,Francesca Binda,Stefano Fagiuoli,Fabiano Di Marco,Luca Lorini,Giuseppe Remuzzi,Steve Whitaker,Gregory Demopulos

Immunobiology（2020）

引用 118|浏览38

暂无评分

摘要

•Narsoplimab down-modulates SARS-CoV-2-induced activation of the lectin pathway and endothelial cell damage.•Narsoplimab can reduce the thrombotic risk of Covid-19 patients.•All patients treated with narsoplimab improved and survived without any drug-related adverse events.

查看译文

关键词

COVID-19,SARS-CoV-2,Narsoplimab,Lectin pathway,Endothelial injury,MASP-2,Thrombosis,Monoclonal antibody

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要